---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007196"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T13:35:17.651531+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study

## Summary
- Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.
- Net loss $17.4M for Q1 2024 vs $12.2M in Q1 2023; R&D expense $17.0M vs $10.2M.
- Fully enrolled Phase 1b FURTHER trial for firmonertinib in NSCLC EGFR PACC mutations; proof-of-concept data expected in 2024.
- Initiated Phase 1b combo study of firmonertinib and ICP-189 (SHP2 inhibitor) for EGFR classical mutation NSCLC.
- Appointed Kristine Peterson to Board; presented preclinical AACR data showing broad activity across uncommon EGFR mutations.

## SEC filing metadata
- accession: 0001558370-24-007196
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/0001558370-24-007196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/avbp-20240508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007196
- JSON: https://secwatch.observer/filing/0001558370-24-007196.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007196.txt

## Key facts
- Earnings Releases
  ArriVent BioPharma, Inc. reported first quarter ended March 31, 2024 results: net income $17.4 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $17.4 million
  - Result: reported results
  source text: Net loss was $17.4 million and $12.2 million for the quarters ended March 31, 2024 and 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/0001558370-24-007196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.